Pramipexole – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 25 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Pramipexole - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Pramipexole is a selective dopamine receptor agonist used in the therapy of Parkinson's disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury. Pramipexole Dihydrochloride is...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Pramipexole is a selective dopamine receptor agonist used in the therapy of Parkinson's disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury. Pramipexole Dihydrochloride is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a non-ergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindication in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Pramipexole is a selective dopamine receptor agonist used in the therapy of Parkinson’s disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury. Pramipexole Dihydrochloride is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a non-ergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain. Compared to other dopamine agonists, the use of this agent may be associated with fewer dyskinetic side effects in treated subjects.

Pramipexole is a member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamine groups, respectively. It has a role as an antiparkinson drug, a dopamine agonist, an antidyskinesia agent, and a radical scavenger. It is a member of benzothiazoles and a diamine. It is a conjugate base of pramipexole(2+).

Pramipexole is a drug used to treat the symptoms of Parkinson’s Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson’s symptoms such as tremors, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson’s Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients, leading to increased difficulty in performing activities of daily living due to symptoms that progress over time. The prevalence of Parkinson’s Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016. This increase may be attributed to an aging population along with other contributing factors. In addition to the above FDA approval for Parkinson’s Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS). RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs.

Mechanism of Action

The exact mechanism of action of pramipexole as a treatment for Parkinson’s disease is unknown at this time. It is thought, however, that the ability of pramipexole to cause stimulation of the dopamine receptors in the striatum of the brain, a region that receives a vast array of neurological input and is responsible for a wide variety of functions, may be involved. Studies performed in animals show that pramipexole influences striatal neuronal transmission rates following the activation of dopamine receptors. Pramipexole is considered a non-ergot dopamine agonist that shows specificity and strong activity at the D2 subfamily of dopamine receptors in vitro, binding selectively and dopamine D2 receptors and showing a preference for the dopamine D3 receptor subtype rather than other subtypes. The clinical significance of this binding specificity is unknown.

or

Our aim was to determine if pramipexole, a D3-preferring agonist, effectively reduced dopamine neuron and fiber loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model when given at intraperitoneal doses corresponding to clinical doses. We also determined whether subchronic treatment with pramipexole regulates dopamine transporter function, thereby reducing intracellular transport of the active metabolite of MPTP, 1-methyl-4-phenylpyridinium (MPP+). Ten 12-month-old C57BL/6 mice were treated with MPTP (or saline) twice per day at 20 mg/kg s.c. (4 injections over 48 h). Mice were pretreated for 3 days and during the 2-day MPTP regimen with pramipexole (0.1 mg/kg/day) or saline. Stereological quantification of dopamine neuron number and optical density measurement of dopamine fiber loss were carried out at 1 week after treatment, using immunostaining for the dopamine transporter (DAT) and tyrosine hydroxylase (TH). Additional wild-type (WT) and D3 receptor knockout (KO) mice were treated for 5 days with pramipexole (0.1 mg/kg/day) or vehicle. The kinetics of (3)H-MPP+ and (3)H-DA uptake (Vmax and Km) were determined 24 hr later; and at 24 hr and 14 days dopamine transporter density was measured by quantitative autoradiography. Pramipexole treatment completely antagonized the neurotoxic effects of MPTP, as measured by substantia nigra and ventral tegmental area TH-immunoreactive cell counts. MPTP– induced loss of striatal innervation, as measured by DAT-immunoreactivity, was partially prevented by pramipexole, but not with regard to TH-IR. Pramipexole also reduced DAT- immunoreactivity in non-MPTP treated mice. Subchronic treatment with pramipexole lowered the Vmax for (3)H-DA and (3)H-MPP+ uptake into striatal synaptosomes of WT mice. Pramipexole treatment lowered Vmax in WT but not D3 KO mice; however, D3 KO mice had lower Vmax for (3)H-DA uptake. There was no change in DAT number in WT with pramipexole treatment or D3 KO mice at 24 hr post-treatment, but there was a reduction in WT-pramipexole treated and not in D3 KO mice at 14 days post-treatment. These results suggest that protection occurs at clinically suitable doses of pramipexole. Protection could be due to a reduced amount of MPP+ taken up into DA terminals via DAT. D3 receptor plays an important role in this regulation of transporter uptake and availability.

Indications

  • This drug is indicated for the symptomatic treatment of Parkinson’s disease. This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS).
  • Sifrol is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or ‘on-off’ fluctuations).
  • Sifrol is indicated for symptomatic treatment of moderate to severe idiopathic restless legs syndrome in dosages up to 0. 54 mg of base (0. 75 mg of salt).
  • Mirapexin is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or ‘on-off’ fluctuations).
  • Mirapexin is indicated for symptomatic treatment of moderate to severe idiopathic restless legs syndrome in dosages up to 0. 54 mg of base (0. 75 mg of salt).
  • Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).
  • Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0. 54 mg of base (0. 75 mg of salt) (see section 4. 2).
  • Pramipexole Teva is indicated for treatment of the signs and symptoms of idiopathic Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or ‘on-off’ fluctuations).
  • Pramipexole Teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0. 54 mg of base (0. 75 mg of salt) (see section 4. 2).
  • Pramipexole Accord is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or ‘on-off’ fluctuations).
  • DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson’s disease in combination with levodopa, i. e. over the course of the disease when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).
  • Restless Legs Syndrome
  • Parkinson’s Disease
  • Periodic Limb Movement Disorder
  • Tardive Dyskinesia

Contraindication

There are no absolute contraindications listed in the product labeling. However, significant warnings and precautions are as below.

  • Falling asleep during activities of daily living: Sudden onset of sleep may occur without warning; advise patients to report symptoms.
  • Symptomatic orthostatic hypotension: Monitor during dose escalation.
  • Impulse control/compulsive behaviors: Patients may experience compulsive behaviors like gambling, excessive shopping, and hypersexuality.
  • Hallucinations and psychotic-like behavior: May occur; risk increases with age.
  • Dyskinesia: May be caused or exacerbated by pramipexole dihydrochloride tablets.
  • Postural deformity: Consider reducing the dose or discontinuing pramipexole dihydrochloride tablets if postural deformity occurs.
  • Special alerts dopamine agonist withdrawal syndrome (DAWS): DAWS may occur after decreasing or discontinuing dopamine agonists and includes symptoms such as panic attacks, insomnia, irritability, anxiety, and depression.

Dosage

Strengths: 0.125 mg; 0.25 mg; 1 mg; 0.5 mg; 1.5 mg; 0.75 mg; 0.375 mg; 3 mg; 4.5 mg; 2.25 mg; 3.75 mg

Parkinson’s Disease

Immediate-release:

  • Initial dose: 0.125 mg orally three times a day
  • Titration: Increase gradually in small dose increments no more frequently than ever 5 to 7 days
  • Maintenance dose: 1.5 to 4.5 mg per day based on efficacy and tolerability
  • Maximum dose: 4.5 mg per day

The following dose titration was used in clinical trials:

  • Week 2, 0.25 mg 3 times a day
  • Week 3, 0.5 mg 3 times a day
  • Week 4, 0.75 mg 3 times a day
  • Week 5, 1 mg 3 times a day
  • Week 6, 1.25 mg 3 times a day
  • Week 7, 1.5 mg 3 times a day.
  • When used in combination with levodopa, the levodopa dose was reduced by an average of 27% from baseline providing a concomitant dose of approximately 800 mg per day.

Extended-release:

  • Initial dose: 0.375 mg orally once a day
  • Titration: Increase gradually no more frequently than every 5 to 7 days, first dose increase should be to 0.75 mg once a day followed by incremental increases of 0.75 mg; assess therapeutic response and tolerability at a minimum of 5 days after each dose increase.
  • Maximum dose: 4.5 mg per day

SWITCHING FROM IMMEDIATE-RELEASE TO EXTENDED-RELEASE:

  • Patients may be switched overnight from immediate-release tablets to extended-release tablets at the same daily dose; monitor closely to determine if dose adjustments may be necessary.

Restless Legs Syndrome

Immediate-release:

  • Initial dose: 0.125 mg orally once a day 2 to 3 hours before bedtime
  • Titration: If needed, the dose may be titrated upwards by increments of 0.125 mg every 4 to 7 days.
    Maximum dose: 0.5 mg orally once a day

Extended-release tablets are not indicated for Restless Legs Syndrome.

  • Doses of 0.75 mg once a day were used in clinical trials but were not found to provide additional benefit as compared to the 0.5 mg dose.

Renal Dose Adjustments

Parkinson’s Disease:
Immediate-release:

  • Very severe renal impairment (CrCl less than 15 mL/min): Not recommended
  • Severe renal impairment (CrCl 15 to less than 30 mL/min): Initial dose: 0.125 mg orally once a day; titrate gradually at intervals of no more frequently than every 5 to 7 days to a maximum dose of 1.5 mg once a day; Maximum dose: 1.5 mg once per day
  • Moderate renal impairment (CrCl 30 to 50 mL/min): Initial dose: 0.125 mg orally twice a day; titrate gradually at intervals of no more frequently than every 5 to 7 days to a maximum dose of 0.75 mg 3 times a day; Maximum dose: 2.25 mg per day
  • Normal to mild renal impairment (CrCl greater than 50 mL/min): No adjustment recommended

Extended-release:

  • Severe renal impairment: Not recommended
  • Moderate renal impairment (CrCl 30 to 50 mL/min): Initial dose: 0.375 mg orally every other day; after 1 week, may increase to once a day dosing based on therapeutic response and tolerability; subsequent dose titrations should be in increments of 0.375 mg no more frequently every 7 days; Maximum dose: 2.25 mg per day
  • Mild renal impairment (CrCl greater than 50 mL/min): No adjustment recommended

Restless Legs Syndrome
Immediate-release:

  • Moderate to severe renal impairment (CrCl 20 to 60 mL/min): Initial dose: 0.125 mg orally once a day 2 to 3 hours before bedtime
    Titration: If needed, the dose may be titrated upwards by increments of 0.125 mg every 14 days; Maximum dose: 0.5 mg orally once a day.

Dose Adjustments

  • If the patient is receiving levodopa, a reduction in the dosage of levodopa should be considered.
  • Patients may be switched overnight from pramipexole immediate-release to pramipexole extended-release at the same daily dose. Dose adjustment may be needed in some patients.

Discontinuation of Treatment:

  • Parkinson’s Disease: Taper off at a rate of 0.75 mg per day until the daily dose has been reduced to 0.75 mg, then reduce by 0.375 mg per day.

Side Effects

The Most Common

  • nausea
  • weakness
  • dizziness
  • loss of balance, falling
  • difficulty falling asleep or staying asleep
  • difficulty remembering
  • abnormal dreams
  • heartburn
  • constipation
  • diarrhea
  • dry mouth
  • swollen, stiff, or painful joints
  • pain in back, arms or legs
  • frequent urination or urgent need to urinate
  • difficulty urinating or pain when urinating

More Common

  • hallucinations (seeing things or hearing voices that do not exist), confusion, aggressive behavior, agitation, abnormal thoughts
  • changes in vision
  • abnormal body movements and motions that you cannot control
  • changes in the way you sit or stand that you cannot control, such as your neck bending forward, bending forward at the waist, or tilting sideways when you sit, stand or walk,
  • dark, red or cola-colored urine
  • muscle pain when an area is touched or pressed. সহজ বাংলা: চাপ দিলে ব্যথা।" data-rx-term="tenderness" data-rx-definition="Tenderness means pain when an area is touched or pressed. সহজ বাংলা: চাপ দিলে ব্যথা।">tenderness
  • muscle stiffness or aching
  • muscle weakness

Rare

  • a light-headed feeling, like you might pass out;
  • hallucinations (seeing or hearing things that are not real);
  • extreme drowsiness, falling asleep suddenly, even after feeling alert;
  • tremors, twitching or uncontrollable muscle movements;
  • unexplained muscle pain, tenderness, or weakness;
  • vision problems; or
  • posture changes you cannot control, such as involuntary bending forward of your neck, bending forward at the waist, or tilting sideways when you sit, stand, or walk.
  • muscle spasm or muscle weakness;
  • drowsiness, dizziness, weakness;
  • confusion, memory problems;
  • dry mouth;
  • nausea, constipation;
  • increased urination; or
  • sleep problems (insomnia), unusual dreams.

Drug Interactions

There may be an interaction between pramipexole and any of the following:

  • alcohol
  • aldesleukin
  • aliskiren
  • alpha agonists (e.g., clonidine, methyldopa)
  • alpha blockers (e.g., alfuzosin, doxazosin, silodosin, tamsulosin)
  • amantadine
  • amifostine
  • amiodarone
  • angiotensin converting enzyme inhibitors (ACEIs; captopril, ramipril)
  • angiotensin receptor blockers (ARBs; e.g., candesartan, irbesartan, losartan)
  • antihistamines (e.g., cetirizine, chlorpheniramine, diphenhydramine, doxylamine, hydroxyzine, loratadine)
  • antipsychotics (e.g., chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone)
  • apomorphine
  • barbiturates (e.g., butalbital, pentobarbital, phenobarbital)
  • benzodiazepines (e.g., alprazolam, diazepam, lorazepam)
  • bortezomib
  • brimonidine
  • buprenorphine
  • bupropion
  • buspirone
  • calcium channel blockers (e.g., amlodipine, diltiazem, nifedipine, verapamil)
  • chloral hydrate
  • cimetidine
  • conivaptan
  • diuretics (water pills; e.g., furosemide, hydrochlorothiazide, triamterene)
  • domperidone
  • duloxetine
  • efavirenz
  • entacapone
  • general anesthetics (medications used to put people to sleep before surgery)
  • guanfacine
  • hydralazine
  • iron sucrose
  • kava kava
  • levodopa
  • methylphenidate
  • metoclopramide
  • minoxidil
  • MAO inhibitors (e.g., moclobemide, phenelzine, rasagiline, selegiline, tranylcypromine)
  • mirtazapine
  • muscle relaxants (e.g., baclofen, cyclobenzaprine, methocarbamol, orphenadrine, tizanidine)
  • nabilone
  • narcotic medications (e.g., codeine, fentanyl, hydromorphone, morphine)
  • nitrates (e.g., nitroglycerin, isosorbide dinitrate, isosorbide mononitrate)
  • obinutuzumab
  • pentoxifylline
  • phosphodiesterase 5 inhibitors (e.g., sildenafil, tadalafil, vardenafil)
  • riociguat
  • ropinirole
  • rotigotine
  • sacubitril
  • scopolamine
  • seizure medications (e.g., carbamazepine, clobazam, levetiracetam, phenobarbital, phenytoin, primidone, topiramate, valproic acid, zonisamide)
  • tapentadol
  • thalidomide
  • tolcapone
  • tramadol
  • tricyclic antidepressants (e.g., amitriptyline, clomipramine, desipramine, trimipramine)
  • zolpidem
  • zopiclone

Pregnancy and Lactation

FDA pregnancy risk category C

Pregnancy

Studies conducted on rats showed that pramipexole could affect fetal development at higher doses. The evidence of teratogenicity remains insufficient. Hence, the advice is to avoid pramipexole during pregnancy. According to the product labeling, there is no adequate data on the developmental risk associated with using pramipexole dihydrochloride tablets in pregnant women.

Breast-feeding

It is not known if pramipexole passes into breast milk. Since the medication reduces the amount of breast milk produced, women who are breastfeeding should not take this medication. According to the package insert, the judgment during breastfeeding and therapy should consider the risk versus benefit to the infant and the benefits of treatment to the mother. Being a dopaminergic agonist, it is contraindicated in lactating mothers since it suppresses lactation. It is around six times more concentrated in milk than in plasma, and hence the risk of transmission to the nursing baby increases. Pramipexole interferes with prolactin secretion in humans, and that may inhibit lactation.

How should this medicine be used?

Pramipexole comes as a tablet and an extended-release (long-acting) tablet to take by mouth. When pramipexole is used to treat Parkinson’s disease, the regular tablet is usually taken three times a day and the extended-release tablet is usually taken once daily. When pramipexole is used to treat restless legs syndrome, the regular tablet is usually taken once a day, 2 to 3 hours before bedtime. Pramipexole extended-release tablets are not used to treat restless legs syndrome. Pramipexole may be taken with or without food, but taking pramipexole with food may help to prevent nausea that may be caused by the medication. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take pramipexole exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the extended-release tablets whole; do not split, chew, or crush them.

Your doctor will start you on a low dose of pramipexole and gradually increase your dose. Your doctor will probably not increase your dose more often than once every 4 to 7 days. It may take several weeks before you reach a dose that works for you.

If you are taking pramipexole to treat restless legs syndrome, you should know that as your treatment continues, your symptoms may worsen, may begin earlier in the evening or afternoon, or may occur in the early morning. Call your doctor if your symptoms worsen or if they begin to occur at different times than in the past.

Pramipexole controls the symptoms of Parkinson’s disease and restless legs syndrome but does not cure these conditions. Continue to take pramipexole even if you feel well. Do not stop taking pramipexole without talking to your doctor. If you are taking pramipexole to treat Parkinson’s disease and you suddenly stop taking the medication, you may experience, fever, confusion, muscle stiffness, a lack of interest or concern for usual activities or things you usually care about, anxiety, depression, tiredness, difficulty falling asleep or staying asleep, sweating, or pain. If you are taking pramipexole to treat restless legs syndrome and you suddenly stop taking the medication, your symptoms may become worse than they were before you started taking this medication. Your doctor will probably decrease your dose gradually.

If you stop taking pramipexole for any reason, do not start to take the medication again without talking to your doctor. Your doctor will probably want to increase your dose again gradually.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

Other uses for this medicine

This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking pramipexole,

  • tell your doctor and pharmacist if you are allergic to pramipexole or any other medications, or any of the ingredients in pramipexole tablets or extended-release tablets. Ask your doctor or pharmacist for a list of the inactive ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antihistamines; cimetidine (Tagamet); medications for allergies, mental illness, and nausea; metoclopramide (Reglan); sedatives; sleeping pills; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you have or have ever had a mental illness, trouble controlling the movement of your muscles,a sleep disorder other than restless legs syndrome, dizziness, fainting, low blood pressure, or kidney disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while taking pramipexole, call your doctor.
  • you should know that pramipexole may make you drowsy or may cause you to suddenly fall asleep during your regular daily activities. You might not feel drowsy before you suddenly fall asleep. Do not drive a car or operate machinery at the beginning of your treatment until you know how pramipexole will affect you. If you suddenly fall asleep while you are doing something such as watching television or riding in a car, or if you become very drowsy, call your doctor. Do not drive or operate machinery until you talk to your doctor.
  • you should know that alcohol can add to the drowsiness caused by this medication. Tell your doctor if you regularly drink alcoholic beverages.
  • you should know that pramipexole may cause dizziness, lightheadedness, nausea, fainting, or sweating when you get up too quickly from a sitting or lying position. This is more common when you first start taking pramipexole, or when your dose is increased. To avoid this problem, get out of the chair or bed slowly, resting your feet on the floor for a few minutes before standing up.
  • you should know that some people who took medications such as pramipexole to treat Parkinson’s disease or restless legs syndrome developed gambling problems, an increased interest in shopping or sex, overeating problems, or other intense urges or behaviors that were compulsive or unusual for them. There is not enough information to tell whether the people developed these problems because they took the medication or for other reasons. Call your doctor if you develop intense urges or have difficulty controlling any of these behaviors. Tell your family members about these risks so that they can call the doctor even if you do not realize that your behavior has become a problem.
  • you should know that if you are taking the extended-release tablets, you may notice something that looks like a swollen tablet or swollen pieces of tablet in your stool. If this happens, especially along with a worsening of your Parkinson’s disease symptoms, call your doctor.

Before you begin taking a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should take this medication.

Behaviour changes: People taking pramipexole have experienced abnormal behaviour such as compulsive gambling, compulsive shopping, hypersexuality, and binge eating. If you experience these symptoms or any other behaviour change while taking this medication, contact your doctor immediately.

Blood pressure: Pramipexole can lower blood pressure for some people. People taking this medication may feel dizzy or lightheaded when rising from a sitting or lying position. Make sure to tell your doctor if you experience this effect. If you have severe heart disease, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.

Drowsiness/sudden onset of sleep: Pramipexole and similar mediations can cause drowsiness and sudden onset of sleep or sleep attacks. Sudden onset of sleep can occur without warning or drowsiness. People taking this medication should avoid driving or operating heavy machinery. If you experience any daytime drowsiness or sudden onset of sleep while taking this medication, contact your doctor immediately.

Hallucinations: People taking this medication should be aware that hallucinations (mainly seeing things that are not really there) can occur and may affect their ability to drive and perform other daily activities. Make sure to tell your doctor if you experience this effect.

Kidney function: Decreased kidney function or kidney disease can cause this medication to build up in the body, causing side effects. People with reduced kidney function should discuss with their doctor how this medication may affect their medical condition, how their medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Pramipexole is not recommended for people with end-stage renal disease.

Melanoma: People with Parkinson’s disease may be at increased risk of developing melanoma (a type of skin cancer). It is not known if this increased risk is due to Parkinson’s disease or to the medications used to treat Parkinson’s disease. Your doctor will monitor you for skin cancer while you are taking this medication. Talk to your doctor if you have any concerns.

Neuroleptic malignant syndrome (NMS): As with other medications that have an effect on movement disorders, pramipexole can trigger a potentially fatal set of symptoms known as neuroleptic malignant syndrome (NMS). If you experience symptoms of NMS, such as high fever; muscle stiffness; confusion or loss of consciousness; sweating; or rapid or irregular heartbeat, seek immediate medical attention.

This is more likely to occur if pramipexole is stopped suddenly or the dose is decreased rapidly. If you are considering stopping this medication, talk with your doctor about the appropriate way to reduce pramipexole.

Restless leg syndrome: When this medication is used to treat the symptoms of restless leg syndrome, it may cause a worsening of symptoms in the early morning hours. It may also cause earlier onset of symptoms in the evening or an increase in symptoms. If you experience this, let your doctor know.

Stopping treatment: Do not stop taking this medication without consulting with your doctor. Stopping this medication suddenly can cause symptoms such as fever, rigid muscles, and blood pressure changes. Other symptoms of depressed mood, fatigue, sweating, trouble sleeping, pain and irritability have also been reported. If you and your doctor decide that stopping this medication is best for you, your doctor will gradually reduce your dose over a week.

Suicidal or agitated behavior: People with Parkinson’s disease are at risk of experiencing thoughts and intentions of self-harm or suicide. These feelings may not pass when the symptoms of PD are relieved. If you have depression or bipolar disorder, you may be at an increased risk of feeling agitated (restless, anxious, aggressive, emotional, and feeling not like themselves), or wanting to hurt yourself or others. If you experience these side effects or notice them in a family member who is taking this medication, contact your doctor immediately.

Children: The safety and effectiveness of using pramipexole have not been established for children.

Seniors: Seniors may be more likely to experience hallucinations (hearing, seeing, or feeling things that are not there) while taking pramipexole.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Pramipexole – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action The exact mechanism of action of pramipexole as a treatment for Parkinson's disease is unknown at this time. It is thought, however, that the ability of pramipexole to cause stimulation of the dopamine receptors in the striatum of the brain, a region that receives a vast array of neurological input and is responsible for a wide variety of functions, may be involved. Studies performed in animals show that pramipexole influences striatal neuronal transmission rates following the activation of dopamine receptors. Pramipexole is considered a non-ergot dopamine agonist that shows specificity and strong activity at the D2 subfamily of dopamine receptors in vitro, binding selectively and dopamine D2 receptors and showing a preference for the dopamine D3 receptor subtype rather than other subtypes. The clinical significance of this binding specificity is unknown. or Our aim was to determine if pramipexole, a D3-preferring agonist, effectively reduced dopamine neuron and fiber loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model when given at intraperitoneal doses corresponding to clinical doses. We also determined whether subchronic treatment with pramipexole regulates dopamine transporter function, thereby reducing intracellular transport of the active metabolite of MPTP, 1-methyl-4-phenylpyridinium (MPP+). Ten 12-month-old C57BL/6 mice were treated with MPTP (or saline) twice per day at 20 mg/kg s.c. (4 injections over 48 h). Mice were pretreated for 3 days and during the 2-day MPTP regimen with pramipexole (0.1 mg/kg/day) or saline. Stereological quantification of dopamine neuron number and optical density measurement of dopamine fiber loss were carried out at 1 week after treatment, using immunostaining for the dopamine transporter (DAT) and tyrosine hydroxylase (TH). Additional wild-type (WT) and D3 receptor knockout (KO) mice were treated for 5 days with pramipexole (0.1 mg/kg/day) or vehicle. The kinetics of (3)H-MPP+ and (3)H-DA uptake (Vmax and Km) were determined 24 hr later; and at 24 hr and 14 days dopamine transporter density was measured by quantitative autoradiography. Pramipexole treatment completely antagonized the neurotoxic effects of MPTP, as measured by substantia nigra and ventral tegmental area TH-immunoreactive cell counts. MPTP- induced loss of striatal innervation, as measured by DAT-immunoreactivity, was partially prevented by pramipexole, but not with regard to TH-IR. Pramipexole also reduced DAT- immunoreactivity in non-MPTP treated mice. Subchronic treatment with pramipexole lowered the Vmax for (3)H-DA and (3)H-MPP+ uptake into striatal synaptosomes of WT mice. Pramipexole treatment lowered Vmax in WT but not D3 KO mice; however, D3 KO mice had lower Vmax for (3)H-DA uptake. There was no change in DAT number in WT with pramipexole treatment or D3 KO mice at 24 hr post-treatment, but there was a reduction in WT-pramipexole treated and not in D3 KO mice at 14 days post-treatment. These results suggest that protection occurs at clinically suitable doses of pramipexole. Protection could be due to a reduced amount of MPP+ taken up into DA terminals via DAT. D3 receptor plays an important role in this regulation of transporter uptake and availability. Indications This drug is indicated for the symptomatic treatment of Parkinson’s disease. This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS). Sifrol is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations). Sifrol is indicated for symptomatic treatment of moderate to severe idiopathic restless legs syndrome in dosages up to 0. 54 mg of base (0. 75 mg of salt). Mirapexin is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations). Mirapexin is indicated for symptomatic treatment of moderate to severe idiopathic restless legs syndrome in dosages up to 0. 54 mg of base (0. 75 mg of salt). Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations). Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0. 54 mg of base (0. 75 mg of salt) (see section 4. 2). Pramipexole Teva is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations). Pramipexole Teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0. 54 mg of base (0. 75 mg of salt) (see section 4. 2). Pramipexole Accord is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i. e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations). DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i. e. over the course of the disease when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations). Restless Legs Syndrome Parkinson's Disease Periodic Limb Movement Disorder Tardive Dyskinesia Contraindication There are no absolute contraindications listed in the product labeling. However, significant warnings and precautions are as below. Falling asleep during activities of daily living: Sudden onset of sleep may occur without warning; advise patients to report symptoms.[rx] Symptomatic orthostatic hypotension: Monitor during dose escalation. Impulse control/compulsive behaviors: Patients may experience compulsive behaviors like gambling, excessive shopping, and hypersexuality.[rx] Hallucinations and psychotic-like behavior: May occur; risk increases with age. Dyskinesia: May be caused or exacerbated by pramipexole dihydrochloride tablets. Postural deformity: Consider reducing the dose or discontinuing pramipexole dihydrochloride tablets if postural deformity occurs. Special alerts dopamine agonist withdrawal syndrome (DAWS): DAWS may occur after decreasing or discontinuing dopamine agonists and includes symptoms such as panic attacks, insomnia, irritability, anxiety, and depression.[rx] Dosage Strengths: 0.125 mg; 0.25 mg; 1 mg; 0.5 mg; 1.5 mg; 0.75 mg; 0.375 mg; 3 mg; 4.5 mg; 2.25 mg; 3.75 mg Parkinson's Disease Immediate-release: Initial dose: 0.125 mg orally three times a day Titration: Increase gradually in small dose increments no more frequently than ever 5 to 7 days Maintenance dose: 1.5 to 4.5 mg per day based on efficacy and tolerability Maximum dose: 4.5 mg per day The following dose titration was used in clinical trials: Week 2, 0.25 mg 3 times a day Week 3, 0.5 mg 3 times a day Week 4, 0.75 mg 3 times a day Week 5, 1 mg 3 times a day Week 6, 1.25 mg 3 times a day Week 7, 1.5 mg 3 times a day. When used in combination with levodopa, the levodopa dose was reduced by an average of 27% from baseline providing a concomitant dose of approximately 800 mg per day. Extended-release: Initial dose: 0.375 mg orally once a day Titration: Increase gradually no more frequently than every 5 to 7 days, first dose increase should be to 0.75 mg once a day followed by incremental increases of 0.75 mg; assess therapeutic response and tolerability at a minimum of 5 days after each dose increase. Maximum dose: 4.5 mg per day SWITCHING FROM IMMEDIATE-RELEASE TO EXTENDED-RELEASE: Patients may be switched overnight from immediate-release tablets to extended-release tablets at the same daily dose; monitor closely to determine if dose adjustments may be necessary. Restless Legs Syndrome Immediate-release: Initial dose: 0.125 mg orally once a day 2 to 3 hours before bedtime Titration: If needed, the dose may be titrated upwards by increments of 0.125 mg every 4 to 7 days. Maximum dose: 0.5 mg orally once a day Extended-release tablets are not indicated for Restless Legs Syndrome. Doses of 0.75 mg once a day were used in clinical trials but were not found to provide additional benefit as compared to the 0.5 mg dose. Renal Dose Adjustments Parkinson's Disease: Immediate-release: Very severe renal impairment (CrCl less than 15 mL/min): Not recommended Severe renal impairment (CrCl 15 to less than 30 mL/min): Initial dose: 0.125 mg orally once a day; titrate gradually at intervals of no more frequently than every 5 to 7 days to a maximum dose of 1.5 mg once a day; Maximum dose: 1.5 mg once per day Moderate renal impairment (CrCl 30 to 50 mL/min): Initial dose: 0.125 mg orally twice a day; titrate gradually at intervals of no more frequently than every 5 to 7 days to a maximum dose of 0.75 mg 3 times a day; Maximum dose: 2.25 mg per day Normal to mild renal impairment (CrCl greater than 50 mL/min): No adjustment recommended Extended-release: Severe renal impairment: Not recommended Moderate renal impairment (CrCl 30 to 50 mL/min): Initial dose: 0.375 mg orally every other day; after 1 week, may increase to once a day dosing based on therapeutic response and tolerability; subsequent dose titrations should be in increments of 0.375 mg no more frequently every 7 days; Maximum dose: 2.25 mg per day Mild renal impairment (CrCl greater than 50 mL/min): No adjustment recommended Restless Legs Syndrome Immediate-release: Moderate to severe renal impairment (CrCl 20 to 60 mL/min): Initial dose: 0.125 mg orally once a day 2 to 3 hours before bedtime Titration: If needed, the dose may be titrated upwards by increments of 0.125 mg every 14 days; Maximum dose: 0.5 mg orally once a day. Dose Adjustments If the patient is receiving levodopa, a reduction in the dosage of levodopa should be considered. Patients may be switched overnight from pramipexole immediate-release to pramipexole extended-release at the same daily dose. Dose adjustment may be needed in some patients. Discontinuation of Treatment: Parkinson's Disease: Taper off at a rate of 0.75 mg per day until the daily dose has been reduced to 0.75 mg, then reduce by 0.375 mg per day. Side Effects The Most Common nausea weakness dizziness loss of balance, falling difficulty falling asleep or staying asleep difficulty remembering abnormal dreams heartburn constipation diarrhea dry mouth swollen, stiff, or painful joints pain in back, arms or legs frequent urination or urgent need to urinate difficulty urinating or pain when urinating More Common hallucinations (seeing things or hearing voices that do not exist), confusion, aggressive behavior, agitation, abnormal thoughts changes in vision abnormal body movements and motions that you cannot control changes in the way you sit or stand that you cannot control, such as your neck bending forward, bending forward at the waist, or tilting sideways when you sit, stand or walk, dark, red or cola-colored urine muscle tenderness muscle stiffness or aching muscle weakness Rare a light-headed feeling, like you might pass out; hallucinations (seeing or hearing things that are not real); extreme drowsiness, falling asleep suddenly, even after feeling alert; tremors, twitching or uncontrollable muscle movements; unexplained muscle pain, tenderness, or weakness; vision problems; or posture changes you cannot control, such as involuntary bending forward of your neck, bending forward at the waist, or tilting sideways when you sit, stand, or walk. muscle spasm or muscle weakness; drowsiness, dizziness, weakness; confusion, memory problems; dry mouth; nausea, constipation; increased urination; or sleep problems (insomnia), unusual dreams. Drug Interactions There may be an interaction between pramipexole and any of the following: alcohol aldesleukin aliskiren alpha agonists (e.g., clonidine, methyldopa) alpha blockers (e.g., alfuzosin, doxazosin, silodosin, tamsulosin) amantadine amifostine amiodarone angiotensin converting enzyme inhibitors (ACEIs; captopril, ramipril) angiotensin receptor blockers (ARBs; e.g., candesartan, irbesartan, losartan) antihistamines (e.g., cetirizine, chlorpheniramine, diphenhydramine, doxylamine, hydroxyzine, loratadine) antipsychotics (e.g., chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone) apomorphine barbiturates (e.g., butalbital, pentobarbital, phenobarbital) benzodiazepines (e.g., alprazolam, diazepam, lorazepam) bortezomib brimonidine buprenorphine bupropion buspirone calcium channel blockers (e.g., amlodipine, diltiazem, nifedipine, verapamil) chloral hydrate cimetidine conivaptan diuretics (water pills; e.g., furosemide, hydrochlorothiazide, triamterene) domperidone duloxetine efavirenz entacapone general anesthetics (medications used to put people to sleep before surgery) guanfacine hydralazine iron sucrose kava kava levodopa methylphenidate metoclopramide minoxidil MAO inhibitors (e.g., moclobemide, phenelzine, rasagiline, selegiline, tranylcypromine) mirtazapine muscle relaxants (e.g., baclofen, cyclobenzaprine, methocarbamol, orphenadrine, tizanidine) nabilone narcotic medications (e.g., codeine, fentanyl, hydromorphone, morphine) nitrates (e.g., nitroglycerin, isosorbide dinitrate, isosorbide mononitrate) obinutuzumab pentoxifylline phosphodiesterase 5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) riociguat ropinirole rotigotine sacubitril scopolamine seizure medications (e.g., carbamazepine, clobazam, levetiracetam, phenobarbital, phenytoin, primidone, topiramate, valproic acid, zonisamide) tapentadol thalidomide tolcapone tramadol tricyclic antidepressants (e.g., amitriptyline, clomipramine, desipramine, trimipramine) zolpidem zopiclone Pregnancy and Lactation FDA pregnancy risk category C Pregnancy Studies conducted on rats showed that pramipexole could affect fetal development at higher doses. The evidence of teratogenicity remains insufficient. Hence, the advice is to avoid pramipexole during pregnancy. According to the product labeling, there is no adequate data on the developmental risk associated with using pramipexole dihydrochloride tablets in pregnant women. Breast-feeding It is not known if pramipexole passes into breast milk. Since the medication reduces the amount of breast milk produced, women who are breastfeeding should not take this medication. According to the package insert, the judgment during breastfeeding and therapy should consider the risk versus benefit to the infant and the benefits of treatment to the mother. Being a dopaminergic agonist, it is contraindicated in lactating mothers since it suppresses lactation. It is around six times more concentrated in milk than in plasma, and hence the risk of transmission to the nursing baby increases. Pramipexole interferes with prolactin secretion in humans, and that may inhibit lactation.[rx] How should this medicine be used?

Pramipexole comes as a tablet and an extended-release (long-acting) tablet to take by mouth. When pramipexole is used to treat Parkinson's disease, the regular tablet is usually taken three times a day and the extended-release tablet is usually taken once daily. When pramipexole is used to treat restless legs syndrome, the regular tablet is usually taken once a day, 2 to 3 hours before bedtime. Pramipexole extended-release tablets are not used to treat restless legs syndrome. Pramipexole may be taken…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   Vasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    Cholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    Imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    A thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    Propylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    Methimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    Mirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)